DIANA SHENK: Open Payments
NPI 1780380741 · BEL AIR, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,236 in 98 payments from 19 companies in 2025. Trend: 2023 $1,260 · 2024 $2,505 · 2025 $2,236
Food & beverage: $2,156Education: $80
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 22 | $461 |
| Regeneron Healthcare Solutions, Inc. | 8 | $273 |
| AstraZeneca Pharmaceuticals LP | 14 | $271 |
| Verona Pharma, Inc. | 14 | $186 |
| JAZZ PHARMACEUTICALS INC. | 5 | $165 |
| Insmed, Inc. | 5 | $113 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $112 |
| Grifols USA, LLC | 4 | $108 |
| Axsome Therapeutics, Inc. | 3 | $95 |
| Vifor Pharma, Inc. | 4 | $84 |
Products named: DUPIXENT, NUCALA, Ohtuvayre, XYWAV, TEZSPIRE, TRELEGY ELLIPTA, AREXVY, FASENRA.
Industry payments across MD — which companies pay providers there.
